Keywords Parole chiave: Dexamethasone, Melphalan, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Thalidomide, Tracer, Adult, Aged, Autologous Bone Marrow Transplantation, Bioaccumulation, Blood Analysis, Cancer Recurrence, Cancer Scintiscanning, Cell Infiltration, Clinical Article, Controlled Study, Correlation Analysis, Dose Response, Drug Efficacy, Drug Response, Drug Uptake, Female, Follow Up, Gastrointestinal Toxicity, Human, Human Cell, Human Tissue, Letter, Multiple Myeloma, Myeloma Cell, Neurotoxicity, Priority Journal, Quantitative Analysis, Scoring System, Urinalysis, 80 And Over, Antineoplastic Agents, Middle Aged, Radiopharmaceuticals, Technetium Tc 99m Sestamibi, Tissue Distribution, Antineoplastic Agents Therapeutic Use
, Bone Marrow Diagnostic Imaging
, Dexamethasone Therapeutic Use
, Melphalan Therapeutic Use
, Multiple Myeloma Diagnostic Imaging Drug Therapy
, Radionuclide Imaging
, Radiopharmaceuticals Pharmacokinetics
, Technetium Tc 99m Sestamibi Pharmacokinetics
, Thalidomide Therapeutic Use,
Affiliations Affiliazioni: *** IBB - CNR ***
Cattedra di Ematologia, Dipto. Medicina Clinica Sperimentale, Università Federico II, via Pansini 5, 80131 Napoli, Italy Cattedra di Medicina Nucleare, Dipto. Scienze Biomorfol. Funzionali, Università Federico II, via Pansini 5, 80131 Napoli, Italy
References Riferimenti: Barlogie, B., Zangari, M., Spencer, T., "Thalidomide in the management of multiple myeloma" (2001) Seminars in Hematology, 38, pp. 250-25
Fonti, R., Del Vecchio, S., Zanetti, A., "Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma" (2001) European Journal of Nuclear Medicine, 28, pp. 214-220
Wakasugi, S., Teshima, H., Nakamura, H., "Tc-99m MIBI localization in bone marrow: A marker of bone marrow malignancy" (1998) Clinical Nuclear Medicine, 23, pp. 664-671
Pace, L., Catalano, L., Pinto, A., "Different patterns of technetium-99m sestamibi uptake in multiple myeloma" (1998) European Journal of Nuclear Medicine, 25, pp. 714-720
Catalano, L., Pace, L., Califano, C., "Detection of focal myeloma lesions by technetium-99m sestarnibi scintigraphy" (1999) Haematologica, 84, pp. 119-124
Svaldi, M., Tappa, C., Gebert, U., "Technetium-99m-sestamibi scintigraphy: An alternative approach for diagnosis and follow-up of active lesions after high dose chemotherapy and autologous stem cell transplantation" (2001) Annals of Hematology, 80, pp. 393-397
99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients [2]
Not available. Non disponibile.
99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients [2]
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(570 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
139 Records (127 escludendo Abstract e Conferenze). Impact factor totale: 430.542 (393.22 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 480.836 (435.546 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:11 260 views visite. Last view on Ultima visita in data Sunday 28 March 2021, 1:36:19